Diabetes Care, Vol 23, Issue 12 1840-1843, Copyright © 2000 by American Diabetes Association

ARTICLES

Effects of cyclo-oxygenase inhibition on vasodilatory response to acetylcholine in patients with type 1 diabetes and nondiabetic subjects

DR Meeking, DL Browne, S Allard, J Munday, PJ Chowienczyck, KM Shaw and MH Cummings
Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Cosham, Portsmouth, UK. dmeeking@aol.com

OBJECTIVE: Studies examining vasodilatory responses to acetylcholine (ACh) and its derivatives have been conflicting. Enhanced activation of the cyclo-oxygenase pathway and increased availability of vasodilatory prostanoids may occur in type 1 diabetes, and this may compensate for the observed reduction in nitric oxide (NO) activity We examined the role of cyclo-oxygenase inhibition on vasodilatory responses in 12 healthy normotensive type 1 diabetic adults and 12 nondiabetic control subjects of similar age, sex, and BMI. RESEARCH DESIGN AND METHODS: Forearm blood flow was measured using a venous occlusion plethysmography technique at baseline and after brachial artery infusions of ACh (7.5, 15, and 30 microg/min). Forearm blood flow at baseline and after ACh was then reexamined after local intra-arterial infusion of indomethacin (0.3 mg/100 ml forearm volume), a cyclo-oxygenase inhibitor. RESULTS: Baseline blood flow in the diabetic and control groups were similar (2.65 +/- 0.26 vs. 2.59 +/- 0.20 ml/min per 100 ml, respectively; P = 0.4). After indomethacin infusion, the vasodilatory responses to all doses of ACh were reduced in both the diabetic (by 25.30 +/- 4.90%) and control group (by 11.23 +/- 5.45%). However, the reduction in blood flow response to ACh after indomethacin was greater in diabetic patients compared with control subjects (P = 0.03). CONCLUSIONS: Our findings suggest that vasodilatory, prostanoids are important in determining endothelial response to ACh in diabetic and nondiabetic subjects. Increased prostaglandin-mediated vasodilation may compensate for attenuated responses to NO previously reported in diabetic subjects. These findings may partly explain the conflicting reports of endothelial dysfunction in patients with type 1 diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. L Browne, D. R Meeking, S. Allard, L. J Munday, K. M Shaw, and M. H Cummings Vasodilator prostanoids compensate for attenuated nitric oxide mediated vasodilation in type 1 diabetes The British Journal of Diabetes & Vascular Disease, November 1, 2007; 7(6): 288 - 294. [Abstract] [PDF]

				W. G. Schrage, N. M. Dietz, J. H. Eisenach, and M. J. Joyner Agonist-dependent variablity of contributions of nitric oxide and prostaglandins in human skeletal muscle J Appl Physiol, April 1, 2005; 98(4): 1251 - 1257. [Abstract] [Full Text] [PDF]

				M. L. Sheu, F. M. Ho, R. S. Yang, K. F. Chao, W. W. Lin, S. Y. Lin-Shiau, and S.-H. Liu High Glucose Induces Human Endothelial Cell Apoptosis Through a Phosphoinositide 3-Kinase-Regulated Cyclooxygenase-2 Pathway Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 539 - 545. [Abstract] [Full Text] [PDF]

				F. A. Dinenno and M. J. Joyner Combined NO and PG inhibition augments {alpha}-adrenergic vasoconstriction in contracting human skeletal muscle Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2576 - H2584. [Abstract] [Full Text] [PDF]

				D. Browne, D. Meeking, K. Shaw, and M. Cummings Review: Endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes -- pathogenesis and identification The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 27 - 34. [Abstract] [PDF]

				S. T. Davidge Prostaglandin H Synthase and Vascular Function Circ. Res., October 12, 2001; 89(8): 650 - 660. [Abstract] [Full Text] [PDF]